NCT06049082View on ClinicalTrials.gov

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
DRUG

KB408 (Nebulization)

Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1

Trial Locations (3)

29425

RECRUITING

Medical University of South Carolina, Charleston

32610

RECRUITING

University of Florida, Gainesville, Gainesville

77380

RECRUITING

Renovatio Clinical, The Woodlands

Sponsors
All Listed Sponsors
lead

Krystal Biotech, Inc.

INDUSTRY

NCT06049082 - A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency | Biotech Hunter | Biotech Hunter